High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Cigna has been treading water for the past six months, recording a small loss of 3.5% while holding steady at $278.80. The stock also fell short of the S&P 500’s 10.8% gain during that period.
UnitedHealth, The Cigna, Humana, Centene and Molina have been highlighted in this Industry Outlook article.
An aging U.S. population, digital transformation, a diversified membership mix and strategic M&A are likely to drive the performance of the Zacks Medical-HMO industry players. UNH, CI, HUM, CNC and MOH are poised to benefit from favorable industry prospects.
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.
Cigna Group stock reacts to TestMu Conference spotlight on AI and reliability Cigna Group (CI) is in focus after the company scheduled a presentation at the 5th TestMu Conference on August 19, 2026, featuring AI and automation engineering lead Nagarjun Adikesavan. The event highlights Cigna Group’s emphasis on quality and reliability in AI driven systems, which matters for investors who are watching how large health insurers apply automation to complex pharmacy and medical benefit...
Cigna Group stock has delivered a 44.4% gain over the past five years, yet the broader valuation checks still suggest the shares screen as undervalued at the recent price of US$277.51. With shorter term returns weaker, investors are left weighing a mixed share price history against a still supportive valuation read. Over five years, Cigna Group has returned 44.4%, which points to solid long term wealth creation despite more recent share price softness. Expectations for the company to keep...
The healthcare giant is wrestling with costs in one part of its business, and the stock's recent dip has investors wondering if this is the moment to step in.
Mark Cuban says AI will never replace radiologists, and his reasoning has nothing to do with capability. The real disruption, he argues, targets a different layer of medicine entirely, one worth hundreds of billions in enterprise value at some of the biggest names in healthcare.
CI's growth and shareholder returns are weighed against rising costs, medical expenses and debt, keeping investors neutral for now.
CVS Health enters the second half of 2026 with stronger earnings and Aetna gains, but medical costs and Caremark risks cloud the recovery.
CVS Health's Q2 EPS jumps more than 40% as Health Care Benefits profitability improves, prompting a major boost to its 2026 AOI outlook.
Let’s dig into the relative performance of Cigna (NYSE:CI) and its peers as we unravel the now-completed Q2 health insurance providers earnings season.
CVS Health is rebuilding momentum as Aetna drives stronger profits and higher 2026 guidance, but medical costs and PBM changes could test the recovery.
Management has raised its full-year earnings outlook twice, and the segment doing most of the lifting is still short of its own target margin.
Cigna Group has lagged the broader market despite consistent earnings performance, while analysts remain moderately optimistic about its future prospects.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Cigna Group stock has delivered a 47.1% total return over the past 5 years, yet current valuation checks still lean toward the shares looking inexpensive rather than fully priced in. In light of recent earnings news and a steady long term track record, investors are weighing whether the recent price of US$282.49 already reflects this progress. Over 5 years, a 47.1% return suggests Cigna Group has rewarded patient shareholders while still inviting a closer look at whether the current price...
Q2 earnings and buybacks put Cigna Group in focus Cigna Group (CI) is back on investors’ radar after reporting its second quarter 2026 results, alongside an update on a long running share repurchase program dating back to 2018. See our latest analysis for Cigna Group. Cigna Group’s latest earnings and long running buyback program have come alongside mixed share price momentum. The stock is up 2.63% on the day and has a modest 1.21% share price return year to date, while the 5 year total...
In the health insurance arena, one company is both the undisputed leader and the most expensive ticket, forcing investors to decide if paying up for quality is a winning strategy.
Investors pay particular attention to a health insurer’s second-quarter report, which reflects more medical claims data among members.
A few sectors have dominated the market this year, and healthcare isn’t one of them. Many stocks in the sector look ready to gain.
UnitedHealth's revenue held up; the operating margin on it did not, and closing that gap is the whole upside case.
CVS Health earnings surged past tepid forecasts after reporting its health benefit costs fell as a share of premiums. The pharmacy chain hiked its full-year outlook by a bit less than the Q2 beat. Analysts say that management's prudence in trying to grow its health benefits business let the company avoid the worst fallout from surprisingly strong medical care utilization.
Investing.com -- Jefferies downgraded Cigna to Hold from Buy, arguing that a growing list of earnings headwinds and limited catalysts outweigh the stock's discounted valuation, while cutting its price target to $307 from $336.
The company published the arithmetic of its own margin repair, and the first hard proof landed a quarter before the shares started compounding.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
